Alkermes (ALKS) Given Daily Media Impact Score of -0.02
Media stories about Alkermes (NASDAQ:ALKS) have been trending somewhat negative on Monday, Accern reports. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alkermes earned a daily sentiment score of -0.02 on Accern’s scale. Accern also assigned media stories about the company an impact score of 47.050925913274 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media stories that may have effected Accern Sentiment’s rankings:
- Pharmalittle: Shire sells cancer biz as Takeda circles; FDA does about-face on Alkermes drug (statnews.com)
- Alkermes (ALKS) Stock: Flying On FDA News (cnafinance.com)
- Thinking about buying stock in Alkermes, Bank of America, CVS Health Corp, The Goldman Sachs Group and Tesla … (prnewswire.com)
- BRIEF-Alkermes Announces FDA Acceptance For Review Of New Drug Application For Alks 5461 (uk.reuters.com)
- In reversal, FDA accepts Alkermes’ depression drug for review (massdevice.com)
A number of equities analysts have weighed in on the company. Credit Suisse Group set a $66.00 price target on Alkermes and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Morgan Stanley reissued an “equal weight” rating and set a $67.00 price target (up previously from $60.00) on shares of Alkermes in a research report on Friday, February 23rd. JPMorgan Chase set a $63.00 price target on Alkermes and gave the stock a “buy” rating in a research report on Tuesday, April 3rd. Cantor Fitzgerald reissued a “hold” rating and set a $50.00 price target on shares of Alkermes in a research report on Tuesday, February 20th. Finally, Citigroup set a $62.00 price target on Alkermes and gave the stock a “hold” rating in a research report on Thursday, February 15th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $61.50.
Alkermes (NASDAQ:ALKS) last posted its earnings results on Wednesday, February 14th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.32. Alkermes had a negative return on equity of 4.32% and a negative net margin of 17.48%. The company had revenue of $275.37 million for the quarter, compared to the consensus estimate of $251.23 million. During the same quarter in the prior year, the business earned $0.02 earnings per share. The firm’s revenue for the quarter was up 29.0% on a year-over-year basis. equities research analysts predict that Alkermes will post -0.57 earnings per share for the current fiscal year.
In other news, SVP Mark Stejbach sold 10,880 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $70.50, for a total value of $767,040.00. Following the transaction, the senior vice president now owns 54,893 shares of the company’s stock, valued at $3,869,956.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Shane Cooke sold 1,700 shares of the company’s stock in a transaction that occurred on Friday, January 26th. The shares were sold at an average price of $60.02, for a total value of $102,034.00. Following the completion of the transaction, the insider now directly owns 76,408 shares in the company, valued at approximately $4,586,008.16. The disclosure for this sale can be found here. Insiders sold 91,673 shares of company stock worth $5,635,250 in the last ninety days. 5.34% of the stock is owned by company insiders.
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.